Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Apr 17, 2015

NanoString nCounter Panels

NanoString Technologies has launched three new products for the nCounter Analysis System: the Immuno-Oncology RNA:Protein Profiling Panel; the PanCancer Progression Panel; and the PanCancer Mouse Immune Profiling Panel.

The Immuno-Oncology RNA:Protein Profiling Panel is a single assay that enables simultaneous measurement of up to 800 RNA and protein targets in minute cancer samples. It is based on the company's PanCancer Immune Profiling panel, which measures 770 RNA and 30 proteins important in immuno-oncology research. NanoString said that this product will initially be available to select customers through an early-access program.

The PanCancer Progression Panel, now available to all customers, addresses key questions about what happens when cancer metastasizes, and includes genes for the study of angiogenesis, epithelial mesenchymal transition, extracellular matrix formation, and metastasis.

The PanCancer Mouse Immune Profiling Panel provides researchers with a tool for pre-clinical immuno-oncology studies.

SoftGenetics' NextGene Software

SoftGenetics has added customized analysis workflow templates provided by RainDance Technologies to its NextGene NGS software. The added templates provide customers of NextGene that use RainDance's ThunderBolts cancer and myeloid panels with pre-defined settings for detecting minor allele frequencies at different sensitivity settings.

Fluxion Biosciences' IsoFlux EMT Enrichment Kit

Fluxion Biosciences has launched its IsoFlux EMT Enrichment Kit for the isolation of rare circulating tumor cells from blood samples. The kit works with the Fluxion's IsoFlux System instrument and specifically targets cells with both epithelial and mesenchymal properties. Fluxion said the kits are available for immediate use through the IsoFlux Discovery Services program, with kit shipments to IsoFlux customers starting in the third quarter of 2015.

Veracyte's Percepta Bronchial Genomic Classifier

Veracyte today announced the launch of its Percepta Bronchial Genomic Classifier test to resolve lung cancer diagnosis after ambiguous bronchscopy. The firm will soon being testing patient samples in its CLIA-certified laboratory.

For more recently launched products and services, please see the New Products page on our website.